The 2021 Global Lung Cancer Therapy Landscape
On June 1st, 2022, LUNGevity Foundation hosted a Facebook Live to discuss our manuscript titled “ The 2021 Global Lung Cancer Therapy Landscape” published in the Journal of
On June 1st, 2022, LUNGevity Foundation hosted a Facebook Live to discuss our manuscript titled “ The 2021 Global Lung Cancer Therapy Landscape” published in the Journal of
The American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago June 3-7, 2022. Dr. Upal Basu Roy, Executive Director of Research at LUNGevity Foundation, sat down with Dr. Charles Rudin to discuss key highlights from ASCO 2022 and what they mean for the lung cancer community.
In 2021, LUNGevity Foundation announced our inaugural Health Equity and Inclusiveness Workforce Development Awards to help combat the lack of diversity among lung cancer
On May 28, 2021, the United States Food & Drug Administration (FDA) approved sotorasib as the first targeted therapy for patients with KRAS G12C-positive non-small cell lung cancer (NSCLC).
MET is a gene that encodes for a MET protein. It is an important signaling protein known to play many different important roles, from the development of embryos to wound healing in
The development of “targeted therapies” which block the function of mutant proteins within tumor cells has revolutionized the treatment landscape for many cancers, most of all lung
Historically, surgery has been the most effective treatment for patients with early-stage non-small cell lung cancer (NSCLC). While technological improvements, such as the
In recent years, biomarker testing has grown increasingly more important and more complex as researchers understand critical details about the molecular basis of lung cancer. By
By now, you have probably heard the news that scientists have discovered a new variant of the virus that causes COVID-19. This one is called omicron, a letter in the Greek alphabet
Some people with lung cancer have reduced lung function from their cancer or their treatments, like surgery, radiation, or chemotherapy. People with diminished lung functional
Checkpoint inhibitor immunotherapy has revolutionized lung cancer treatment and ushered in a new era of scientific discovery that is focused on empowering our natural immune system
Editor's Note: Post was updated on 10/21 with new recommendations and authorizations. There has been a lot of information recently about COVID-19 boosters and who should get them